Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AX-024.HCl in Healthy Males
NCT02546635Phase 1Completed
- Sponsor
- Artax Biopharma
- Start
- Aug 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AX-024 in autoimmune diseases (2 arms), sponsored by Artax Biopharma. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 10 days. Started Aug 2015; status: completed.
02
Drugs
AX-024
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT02546635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546635.